Bayer announced that Kerendia® (finerenone) (10mg and 20mg), an oral, first-in-class non-steroidal, selective mineralocorticoid receptor (MR) antagonist,2 has been accepted for use within NHS Scotland by The Scottish Medicines Consortium (SMC) for the treatment of chronic kidney disease (stage 3 and 4 with albuminuria)
The pandemic has pushed the NHS to breaking point. Waiting lists have never been longer, waiting times in A&E are at a record level and inpatient beds and healthcare staff to manage them are in extreme short supply.